Previous Statements by MYL
» Mylan's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Mylan, Inc. - Analyst/Investor Day
» Mylan's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Shareholders of the EpiPen maker also re-elected the board at the June 22 annual meeting.
The pharmaceutical company has bought 99% stakes in five coal processing companies since 2011.
The firm sees a lot that can drive shares higher but isn't sure that these 'positive catalysts will occur.'
Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.